<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Micro- or macroalbuminuria is associated with increased <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e> among patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, but whether <z:mp ids='MP_0002871'>albuminuria</z:mp> within the <z:mpath ids='MPATH_458'>normal</z:mpath> range predicts long-term cardiovascular risk is unknown </plain></SENT>
<SENT sid="1" pm="."><plain>We evaluated the relationships between <z:mp ids='MP_0002871'>albuminuria</z:mp> and cardiovascular events in 1208 hypertensive, normoalbuminuric patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> from the BErgamo NEphrologic <z:mp ids='MP_0002055'>Diabetes</z:mp> Complication Trial (BENEDICT), <z:hpo ids='HP_0000001'>all</z:hpo> of whom received <z:chebi fb="0" ids="35457">angiotensin-converting enzyme inhibitor</z:chebi> (ACEI) therapy at the end of the trial and were followed for a median of 9.2 years </plain></SENT>
<SENT sid="2" pm="."><plain>The main outcome was time to the first of fatal or nonfatal <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo>; <z:hpo ids='HP_0001297'>stroke</z:hpo>; coronary, carotid, or peripheral artery revascularization; or hospitalization for <z:hpo ids='HP_0001635'>heart failure</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Overall, 189 (15.6%) of the patients experienced a main outcome event (2.14 events/100 patient-years); 24 events were fatal </plain></SENT>
<SENT sid="4" pm="."><plain><z:mp ids='MP_0002871'>Albuminuria</z:mp> independently predicted events (hazard ratio [HR], 1.05; 95% confidence interval [CI], 1.02-1.08) </plain></SENT>
<SENT sid="5" pm="."><plain>Second-degree polynomial multivariable analysis showed a continuous nonlinear relationship between <z:mp ids='MP_0002871'>albuminuria</z:mp> and events without thresholds </plain></SENT>
<SENT sid="6" pm="."><plain>Considering the entire study population, even <z:mp ids='MP_0002871'>albuminuria</z:mp> at 1-2 μg/min was significantly associated with increased risk compared with <z:mp ids='MP_0002871'>albuminuria</z:mp> &lt;1 μg/min (HR, 1.04; 95% CI, 1.02-1.07) </plain></SENT>
<SENT sid="7" pm="."><plain>This relationship was similar in the subgroup originally randomly assigned to non-ACEI therapy </plain></SENT>
<SENT sid="8" pm="."><plain>Among those originally receiving ACEI therapy, however, the event rate was uniformly low and was not significantly associated with <z:mp ids='MP_0002871'>albuminuria</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>Taken together, among normoalbuminuric patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, any degree of measurable <z:mp ids='MP_0002871'>albuminuria</z:mp> bears significant cardiovascular risk </plain></SENT>
<SENT sid="10" pm="."><plain>The association with risk is continuous but is lost with early ACEI therapy </plain></SENT>
</text></document>